X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs PIRAMAL ENTERPRISES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA PIRAMAL ENTERPRISES ABBOTT INDIA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 39.4 9.1 432.3% View Chart
P/BV x 11.4 3.0 377.3% View Chart
Dividend Yield % 0.5 0.8 66.7%  

Financials

 ABBOTT INDIA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
ABBOTT INDIA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs5,1902,095 247.7%   
Low Rs4,3511,025 424.5%   
Sales per share (Unadj.) Rs1,382.9492.8 280.6%  
Earnings per share (Unadj.) Rs130.272.6 179.4%  
Cash flow per share (Unadj.) Rs137.994.7 145.7%  
Dividends per share (Unadj.) Rs40.0021.00 190.5%  
Dividend yield (eoy) %0.81.3 62.3%  
Book value per share (Unadj.) Rs652.7862.5 75.7%  
Shares outstanding (eoy) m21.25172.56 12.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.2 109.0%   
Avg P/E ratio x36.621.5 170.4%  
P/CF ratio (eoy) x34.616.5 209.9%  
Price / Book Value ratio x7.31.8 404.1%  
Dividend payout %30.728.9 106.2%   
Avg Mkt Cap Rs m101,373269,194 37.7%   
No. of employees `0003.14.0 76.8%   
Total wages/salary Rs m3,45317,939 19.2%   
Avg. sales/employee Rs Th9,531.921,190.3 45.0%   
Avg. wages/employee Rs Th1,119.94,470.1 25.1%   
Avg. net profit/employee Rs Th897.33,120.0 28.8%   
INCOME DATA
Net Sales Rs m29,38785,037 34.6%  
Other income Rs m5762,338 24.7%   
Total revenues Rs m29,96387,374 34.3%   
Gross profit Rs m3,97334,991 11.4%  
Depreciation Rs m1643,817 4.3%   
Interest Rs m2020,310 0.1%   
Profit before tax Rs m4,36513,202 33.1%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m1,5982,281 70.1%   
Profit after tax Rs m2,76712,520 22.1%  
Gross profit margin %13.541.1 32.9%  
Effective tax rate %36.617.3 211.9%   
Net profit margin %9.414.7 63.9%  
BALANCE SHEET DATA
Current assets Rs m18,90687,590 21.6%   
Current liabilities Rs m6,297185,578 3.4%   
Net working cap to sales %42.9-115.2 -37.2%  
Current ratio x3.00.5 636.2%  
Inventory Days Days6231 200.3%  
Debtors Days Days2248 45.5%  
Net fixed assets Rs m1,159108,523 1.1%   
Share capital Rs m213345 61.6%   
"Free" reserves Rs m13,657148,481 9.2%   
Net worth Rs m13,869148,826 9.3%   
Long term debt Rs m0144,957 0.0%   
Total assets Rs m20,638482,394 4.3%  
Interest coverage x215.01.7 13,027.9%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x1.40.2 807.8%   
Return on assets %13.56.8 198.4%  
Return on equity %19.98.4 237.1%  
Return on capital %31.612.0 264.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m015,001 0.0%   
Fx outflow Rs m05,150 0.0%   
Net fx Rs m09,851 0.0%   
CASH FLOW
From Operations Rs m3,072-100,393 -3.1%  
From Investments Rs m-1,554-24,202 6.4%  
From Financial Activity Rs m-898135,705 -0.7%  
Net Cashflow Rs m62111,110 5.6%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 4.0 197.5%  
FIIs % 0.1 26.6 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 16.5 103.6%  
Shareholders   18,270 93,274 19.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFE  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jun 22, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS